RxDoctor Payments Data

James McAlpine

Internal Medicine · Simpsonville, SCNPI 1285020958

Payments from drug & device makers

$3,402in general payments, 2019–2025

Across 200 payments — averaging $17.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$381
  • Lilly USA, LLC$345
  • Novo Nordisk$332
  • Amgen$278
  • Novartis$265
  • AbbVie$260
  • plus $2K from 42 others

What the payments were for

  • Food & beverage$3,391100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,402 in reported general payments places this provider in the 80th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$184,456
Medicare patients
270
Services billed
7,650

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide253$336,583
OzempicSemaglutide130$156,483
EliquisApixaban78$82,379
JardianceEmpagliflozin66$75,981
XareltoRivaroxaban30$39,891
FarxigaDapagliflozin Propanediol26$32,608
Tresiba Flextouch U-200Insulin Degludec25$23,729
Repatha SureclickEvolocumab27$19,822
Tresiba Flextouch U-100Insulin Degludec19$6,855
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$6,235
Testosterone12$5,505
Atorvastatin Calcium283$2,880
Wixela InhubFluticasone Propion/Salmeterol15$2,705
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$2,612
SynthroidLevothyroxine Sodium26$2,542

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$345$336,583253 claims
Novo NordiskOzempic$332$156,483130 claims
PfizerEliquis, Premarin$133$84,72990 claims
Boehringer IngelheimJardiance$35$75,98166 claims
AstraZenecaFarxiga$112$32,60826 claims
AbbVieSynthroid$260$2,54226 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$15$2,286228 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Simpsonville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →